Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Harvard Business School
McKinsey
Medtronic

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,809,330

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,809,330
Title:Pyrazolo[1,5-A]pyrimidines for antiviral treatment
Abstract: The invention provides compounds of Formula I or Formula II: ##STR00001## or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Inventor(s): Babaoglu; Kerim (Pacifica, CA), Boojamra; Constantine G. (San Francisco, CA), Eisenberg; Eugene J. (San Carlos, CA), Hui; Hon Chung (San Mateo, CA), Mackman; Richard L. (Milbrae, CA), Parrish; Jay P. (Redwood City, CA), Sangi; Michael (Oakland, CA), Saunders; Oliver L. (San Mateo, CA), Siegel; Dustin (Foster City, CA), Sperandio; David (Palo Alto, CA), Yang; Hai (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/069,685
Patent Claims:1. A method of treating a Pneumovirinae virus infection in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound of formula: ##STR00774## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the Pneumovirinae virus infection is caused by human respiratory syncytial virus.

3. The method of claim 1 further comprising administering a therapeutically effective amount of at least one other therapeutic agent selected from ribavirin, palivizumab, motavizumab, RSV-IGIV, MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 and ALX-0171, or mixtures thereof.

4. The method of claim 1 wherein the therapeutically effective amount is a daily dose of from 1 mg to 1,000 mg administered in a single dose or multiple doses.

5. The method of claim 4 wherein the therapeutically effective amount is administered orally.

6. The method of claim 5 wherein the therapeutically effective amount is administered in an aqueous solution or suspension.

7. The method of claim 1 wherein the therapeutically effective amount is a daily dose of from 5 mg to 500 mg administered in a single dose or multiple doses.

8. The method of claim 7 wherein the therapeutically effective amount is administered orally.

9. The method of claim 7 wherein the therapeutically effective amount is administered in an aqueous solution or suspension.

10. The method of claim 1 wherein the pharmaceutically acceptable salt is a trifluoroacetic acid salt.

Details for Patent 8,809,330

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2030-06-24 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2030-06-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,809,330

Country Patent Number Publication Date
South Africa 201209549 Jul 29, 2015
World Intellectual Property Organization (WIPO) 2011163518 Dec 29, 2011
Uruguay 33467 Jan 31, 2012
United States of America 2012003215 Jan 05, 2012
United States of America 2014072554 Mar 13, 2014
United States of America 2014154240 Jun 05, 2014
United States of America 2016130275 May 12, 2016
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Dow
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.